Diversified Consumer Services
Company Overview of University of Minnesota
University of Minnesota is an educational institution that provides undergraduate and graduate programs. It offers courses in business administration, agriculture and life sciences, arts, medicine, engineering, mathematics, nursing and health sciences, and social services. University of Minnesota was founded in 1851 and is based in Minneapolis, Minnesota.
Minneapolis, MN 55455
Founded in 1851
Key Executives for University of Minnesota
President and Board of Regents
Vice President of Research
Vice President of Health Sciences and Dean of Medical School
Vice President for University Relations
Compensation as of Fiscal Year 2014.
University of Minnesota Key Developments
Cellectis Plant Sciences, Inc. Signs License Agreement with the University of Minnesota
Apr 16 15
Cellectis plant sciences Inc. has announced that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide rights to use the technology covered by the patent rights of the family WO/2014/144155 entitled "Engineering Plant Genomes Using CRISPR/Cas Systems". In addition to meganucleases and TALEN (TradeMark) technology, this approach for targeted modification of plant genomes was developed by the laboratory of Professor Dan Voytas in the University of Minnesota. The technology has demonstrated results in plant genome engineering and adds to Cellectis plant sciences Inc. strong intellectual property rights in the gene editing field, in addition to meganuclease and TALENTM technologies. Similarly to meganucleases, Zinc Fingers and TALEN (TradeMark), CRISPR technology enables a number of useful tools to target specific loci in a genome and/or modulate the expression of genes. The technology is based on novel sequence-specific nucleases that can be cheaply engineered to recognize any gene of interest in a genome. Application in plants, similarly to the other gene editing technologies, could enable the development of valuable crops.
U of M Plans To Sell Midway Building
Feb 4 15
University of Minnesota (U of M) is planning to sell an office and warehouse building in St. Paul's Midway area.
RedHill Biopharma Ltd. Acquires Rights of Patented Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program
Dec 18 14
RedHill Biopharma Ltd. announced that it has entered into a license agreement with the University of Minnesota to acquire the rights to a patented technology to support the development of a commercial diagnostic test for detection of Mycobacterium avium subspecies paratuberculosis (‘MAP’) bacterium. The company’s Crohn's disease program RHB-104, currently undergoing a first Phase III study in the U.S., Canada and Israel, is based on increasing evidence supporting the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients. There is currently no validated, commercially available method of detecting the presence or absence of MAP in patients suffering from Crohn's disease and other diseases. As part of its development efforts for RHB-104, RedHill is developing, in collaboration with Quest Diagnostics, a diagnostic test to aid in detecting the presence of MAP in whole blood. The patents acquired from the University of Minnesota are intended to support the ongoing development and validation of this diagnostic test in current and future clinical studies. The company will pay the University of Minnesota a one-time upfront payment and an additional potential milestone payment for the licensed technology. A pre-submission meeting with the FDA to discuss the development path for the diagnostic test is scheduled for January 2015. Currently in a first Phase III study for the treatment of Crohn's disease (the MAP US study), RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHB-104 is based on increasing evidence supporting the hypothesis that Crohn's disease is caused by the Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. The RHB-104 formulation was originally developed by Professor Thomas Borody, a leading innovator of therapeutic approaches to treating gastrointestinal tract diseases, who also developed the original triple therapy for peptic ulcer disease associated with H. pylori. Several clinical trials were conducted with earlier formulations of RHB-104, including an Australian Phase III study conducted by Pfizer. The company has conducted several supportive studies with the current formulation of RHB-104 and a long-term population pharmacokinetic (Pop-PK) study is ongoing as part of the Phase III MAP US study. The formulation of RHB-104 is covered by several issued and pending patents.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|